ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
LncRNA HOXA11-AS Promotes Myocardial Injury in Chronic Heart Failure by Sponging miR-342-3p.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveLncRNA HOXA11-AS was abnormally upregulated during heart failure, suggesting that it might be involved in the development of chronic heart failure (CHF). This study aims to explore the diagnostic value of HOXA11-AS in CHF and its mechanism of action in myocardial injury.MethodsThe level of HOXA11-AS in serum was detected by real-time quantitative polymerase chain reaction (RT-qPCR), and its diagnostic efficacy was evaluated by ROC curve. The model of CHF was established by treating AC16 cells with doxorubicin (DOX). Cell viability and apoptosis were detected by cell counting kit-8 (CCK-8) and flow cytometry. The levels of inflammatory factors and myocardial injury markers were detected by enzyme-linked immunosorbent assay (ELISA). The content of malondialdehyde (MDA) and the activity of superoxide dismutase (SOD) were detected by kits. Dual-luciferase reporter assay was used to verify the targeting relationship between HOXA11-AS and miR-342-3p.ResultsThe expression of HOXA11-AS in the serum of CHF patients was significantly increased. ROC analysis showed that HOXA11-AS had a high diagnostic value for CHF. In the DOX-induced cell model, knocking down HOXA11-AS could significantly enhance cell viability, inhibit cell apoptosis, and reduce the release of myocardial injury markers, pro-inflammatory factors, as well as the level of oxidative stress. miR-342-3p was the target gene of HOXA11-AS. Inhibition of miR-342-3p could reverse the myocardial protective effect produced by the knockout of HOXA11-AS.ConclusionHOXA11-AS, as a potential biomarker for diagnosing CHF, exacerbates myocardial injury, inflammatory response and oxidative stress by sponging miR-342-3p.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.